311 Effects of ruxolitinib cream in patients with atopic dermatitis with head and/or neck involvement

Abstract

Atopic dermatitis (AD) often involves the head and/or neck (HN). In two phase 3 studies (TRuE-AD1, TRuE-AD2), 1249 patients (≥12 y) with AD for ≥2 y, an Investigator’s Global Assessment (IGA) score of 2/3, and 3%–20% affected body surface area were randomized (2:2:1) to twice-daily 0.75% or 1.5% ruxolitinib (RUX) cream (Janus kinase [JAK] 1/JAK2 inhibitor) or vehicle cream for 8 weeks of double-blind treatment. In this analysis, pooled efficacy at Week 8 was assessed by the proportion of patients achieving IGA treatment success (IGA of 0/1 and ≥2-grade improvement from baseline), ≥75% improvement in Eczema Area and Severity Index (EASI-75) vs baseline, and ≥4-point improvement in itch Numerical Rating Scale score (NRS4) in patients who had HN involvement at baseline (n=696 [55.7% of randomized patients]); data in the overall population (OP) were also included.